Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer

Similar documents
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008

RESEARCH ARTICLE. Abstract. Introduction

Role of Surgery in Cervical Cancer & Research Questions

Prognostic significance of positive lymph node number in early cervical cancer

ECC or Margins Positive?

Gynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial

Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic

Original Article. Introduction. Soyi Lim 1, Seok-Ho Lee 2, Kwang Beom Lee 1, Chan-Yong Park 1

Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix

ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data

Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy

The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer

Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

RESEARCH ARTICLE. Abstract. Introduction. Materials and Methods

RESEARCH ARTICLE. Abstract. Introduction

17 th ESO-ESMO Masterclass in clinical Oncology

Comparison of outcomes between squamous cell carcinoma and adenocarcinoma in patients with surgically treated stage I II cervical cancer

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous

Algorithms for management of Cervical cancer

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

ORIGINAL PAPER. Department of Radiology, Nagoya University Graduate School of Medicine, Aichi, Japan 2

Correspondence should be addressed to Dae Sik Yang;

The Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer

The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

surgical staging g in early endometrial cancer

Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Ovarian Transposition for Stage Ib Squamous Cell Cervical Cancer - Lack of Effects on Survival Rates?

Factors associated with parametrial involvement in patients with stage IB1 cervical cancer: who is suitable for less radical surgery?

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

CPC on Cervical Pathology

Tae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum Paek 1,2, Yonghee Lee 1,3, Eun Ju Lee 1,4, Suk-Joon Chang 1,2, Hee-Sug Ryu 1,2

Lei Li 1*, XiaoYan Song 2, RuoNan Liu 1, Nan Li 1, Ye Zhang 1, Yan Cheng 1, HongTu Chao 1 and LiYing Wang 1

Chapter 8 Adenocarcinoma

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

Prognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis

Original Article The significance of perineural invasion as a prognostic factor in cervical cancer patients of different ethnicities

Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix

Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer

Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?

Key words: Cervix, Modified field, Radiotherapy, Small field, Wertheim s hysterectomy

receive adjuvant chemotherapy

Locally advanced disease & challenges in management

Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy

Staging and Treatment Update for Gynecologic Malignancies

Original Article. Introduction. Tae-Kyu Jang, So-Jin Shin, Hyewon Chung, Sang-Hoon Kwon, Soon-Do Cha, Eunbi Lee, Changmin Shin, Chi-Heum Cho

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria

What We Have Learned from Over 1400 Radical Hysterectomy Operations in Chiang Mai University Hospital

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Chapter 5 Stage III and IVa disease

PROMISING TREATMENT RESULTS OF ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL HYSTERECTOMY FOR INTERMEDIATE RISK STAGE 1B CERVICAL CANCER

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

Factors Predicting Pelvic Lymph Node Metastasis, Relapse, and Disease Outcome in Pattern C Endocervical Adenocarcinomas

Fertility-sparing surgery in young patients with cervical cancer

Papillary serous carcinoma of the uterine cervix: a clinicopathological analysis of 4 cases and a literature review

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA

Possibility of less radical treatment for patients with early invasive uterine cervical cancer

Why Radical Trachelectomy and not Radical Hysterectomy for the treatment of early stage cervical cancer?

Cervical Cancer Guidelines L and SC Network July Introduction:

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals

Independent risk factors for ovarian metastases in stage IA IIB cervical carcinoma

Role and Techniques of Surgery in Carcinoma Cervix. Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh

Evolution of radical hysterectomy for cervical cancer along the last two decades: single institution experience

Cervical Cancer: 2018 FIGO Staging

Impact of body mass index on the prognosis of Korean women with endometrioid adenocarcinoma of the uterus: A cohort study

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

Lymphovascular Invasion Is a Significant Predictor for Distant Recurrence in Patients With Early-Stage Endometrial Endometrioid Adenocarcinoma

Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer

Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?

Predictors and Patterns of recurrence after radical surgery in ampulla of vater cancer: Comparison analysis between early and late recu rrence.

Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)

Janjira Petsuksiri, M.D

Risk Factors for Failing Cervical Cancer. Time of Simple Hysterectomy

Cervical Cancers Treatment Guideline KMHK

Postoperative Radiotherapy for Patients with Invasive Cervical Cancer Following Treatment with Simple Hysterectomy

Enterprise Interest None

Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-institutional analysis of 608 women

Division of Radiation Oncology, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa b

MRI for cervical and endometrial cancers. Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB

Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?

Clinical Pathological Conference. Malignant Melanoma of the Vulva

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma

GCIG Rare Tumour Brainstorming Day

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

An Alternative Triage Strategy Based on Preoperative MRI for Avoiding Trimodality Therapy in Stage IB Cervical Cancer

Coversheet for Network Site Specific Group Agreed Documentation

Oncologic effectiveness of nerve-sparing radical hysterectomy in cervical cancer

Effectiveness of cervical cancer therapy using neoadjuvant chemotherapy in combination with radical surgery: a metaanalysis

Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy

Prognostic Impact of Histology in Patients with Cervical Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Neuroendocrine Carcinoma

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

Transcription:

대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D.

Cervical cancer The 3 th most common cancer in women worldwide. Early cervical cancer (FIGO stage IA2~IIA) Surgery or Radiotherapy Overall survival rate at 5 years; 80% 90% But, Many other factors influence to treatment outcome. Parkin et al 2005 CA cancer J clin Samlal RA,et al1999.(ejog Reprod Biol)

Prognostic factors in early stage cervical cancer High risk factors Positive or close margins Positive lymph nodes Microscopic parametrial involvement Intermediate-risk factors Large mass size Deep cervical stromal invasion Lymph-vascular space invasion Fuller AF, et al. (Gynecol Oncol) 1989 Delgado G, et al. (Gynecol Oncol) 1990

Adjuvant treatment with risk factors

Objective To investigate the prognostic significance of intermediate risk factors such as large mass size, deep stromal invasion, lymphovascular space invasion and their correlation with high risk factors.

Patients and methods Patients 105 patients with cervical cancer stage la2- lla Radical hysterectomy between 2003 and 2007 at SNUBH Adjuvant therapy if indicated Intermediate risk score Definition of Intermediate risk factor Large mass size (> 4cm) Deep cervical stromal invasion ( 50%) Lymph-vascular space invasion Scoring of number of intermediate risk factor (0 to 3)

Results

Association of clinicopathologic factors with intermediate risk score 0 (n=30) n (%) Score of intermediate risk factors 1 (n=27) 2 (n=22) n (%) n (%) 3 (n=26) n (%) P Age <50 14 (46.7%) 14 (51.9%) 11 (50.0%) 13 (50.0%) 50 16 (53.3%) 13 (48.1%) 11 (50.0%) 13 (50.0%) 0.983 * Stage 1a2 1 (3.3%) 1 (3.7%) 0 (0%) 0 (0%) 1b1 27 (90.0%) 16 (59.3%) 3 (13.6%) 0 (0%) < 0.001 1b2 0 (0%) 2 (7.4%) 8 (36.4%) 10 (38.5%) 2a 2 (6.7%) 8 (29.6%) 11 (50.0%) 16 (61.5%) Histologic type Squamous 25 (83.3%) 17 (63.0%) 17 (77.3%) 21 (80.8%) 0.50 * others 5 (16.7%) 10 (37.0%) 5 (22.7%) 5 (19.2%) Adjuvant Tx. No 28 (93.3%) 14 (51.9%) 5 (22.7%) 3 (11.5%) Yes 2 (6.7%) 13 (48.1%) 17 (77.3%) 23 (88.5%) < 0.001 * Recur No 28 (93.3%) 26 (96.3%) 20 (90.9%) 23 (88.5%) 0.74 * Yes 2 (6.7%) 1 (3.7%) 2 (9.1%) 3 (11.5%) n = number of case, % = % of case within risk score. *= Chi-square test. =linear-by-linear association.

Correlation with intermediate risk score and high risk factors Patients with positive high risk factors(%) 100% 80% p < 0.001 60% 40% 29.6% 20% 0% 0.0% 84.6% 68.2% 0 (0/30) 1 (8/27) 2 (15/22) 3 (22/26) Intermediate risk score(case/total) Correlation with intermediate risk score & number of high risk factors 1.4 1.2 1 0.8 0.6 0.4 0.2 0 p < 0.001 0 0.41 1 0 1 2 3 1.4 Intermediate risk score

Correlation with intermediate risk score and high risk factors Patients of positive prametrial invasion (%) Patients of resection margin involvement(%) 100% 20% 80% 60% p < 0.001 65.4% 15% p < 0.025 15.4% 40% 40.9% 10% 20% 25.7% 5% 4.5% 0% 0.0% 0 (0/30) 1 (3/27) 2 (9/22) 3 (17/26) Intermediate risk score(case/total) 0% 0.0% 0.0% 0 (0/30) 1 (0/27) 2 (1/22) 3 (4/26) Intermediate risk score(case/total)

Increasing of LN involvement with intermediate risk score 80% 60% Patients with LN involvement (%) 65.4% p < 0.001 54.5% 40% 29.6% 20% 0% 0.0% 0 (0/30) 1 (8/27) 2 (12/22) 3 (17/26) Intermediate risk score(case/total) Mean LN number according to intermediate risk score 5 4 3 2 1 0 p = 0.023 0 1.7 2.6 4.4 0 1 2 3 Intermediate risk score

Treatment Plan Considering Risk Factor Stage IA2~IIA -> RH c PLND High risk factors(+) ; Adjuvant CCRT High risk factor(-) Intermediate risk factors(+) ; Adjuvant therapy Intermediate risk factor(-) ; Observation

Conclusion Number of intermediate risk factors was statically significant associated with presence of high risk factors. Our intermediate risks scoring system 1. Patients with intermediate risk factors are more favorable to receive adjuvant treatment even if without high risk factor. 2. Incidental early cervical cancer patients without any intermediate risk factor after simple hystrectomy can be observed instead of reoperation.

Thanks for your attention

Patients with Intermediate risk factor Schorge JO, et al. in 1997 Recurrence with no difference between radical hysterectomy(rh) and RH+RT. Alexander S, et al. in 1999 Adjuvant pelvic RT reduced recurrence from 28% to 15% at 2 years after treatment. Ayhan A, et al. in 2004 Adjuvant RT in stage IB cervical cancer with negative node provides no survival advantage.

Study for correlation of intermediate risk factor with LN metastasis Journal LVSI DSI Size Gauthier P, et al. (1985) Fuller AF, et al. (1989) Delgado G, et al. (1989) NS S NS S a S a S a S S S LN ; lymph node, LVSI ; lympho-vascular space invovement, DSI ; deep stromal invasion. NA ; not analysis, S ; significant, NS ; not significant. a ; as determined by univariate analysis

Scoring of intermediate risk factor Gauthier P, et al. in 1985 Grouping Factors 5yr survival Low Intermediate 2cm sized 2.1~3cm + 1.5cm invasion 2.1~3cm + >1.5cm invasion > 3cm sized + 1.5cm invasion 97% 71% High > 3cm sized + > 1.5cm invasion 31% G. Delgado, et al. in 1990 A. Sedlis, et al. in 1999 LVSI Stromal invasion Tumor size Positive Positive Positive Negative Deep 1/3 Middle 1/3 Superficial 1/3 Deep or middle 1/3 Any 2cm 5cm 4cm

A Gynenologic Oncology Group Study in 1990

Scoring of intermediate risk factor Gauthier P, et al. in 1985 Grouping Factors 5yr survival Low Intermediate 2cm sized 2.1~3cm + 1.5cm invasion 2.1~3cm + >1.5cm invasion > 3cm sized + 1.5cm invasion High > 3cm sized + > 1.5cm invasion 31% 97% 71% G. Delgado, et al. in 1990 A. Sedlis, et al. in 1999 LVSI Stromal invasion Tumor size Positive Positive Positive Negative Deep 1/3 Middle 1/3 Superficial 1/3 Deep or middle 1/3 Any 2cm 5cm 4cm

Correlation with recurrence rate with intermediate risk score Score of intermediate risk factors 0 (n=30) n (%) 1 (n=19) n (%) 2 (n=7) n (%) 3 (n=4) n (%) P No high risk yes 2 (6.7%) 1 (5.3%) 2 (28.6%) 0 (0%) 0.738 no 28 (93.3%) 18 (94.7%) 5 (71.4%) 4 (100%) Score of intermediate risk factors 0 (n=28) n (%) 1 (n=13) n (%) 2 (n=4) n (%) 3 (n=2) n (%) P No high risk + No Adjuvant Tx. yes 1 (3.6%) 0 (0%) 2 (50.0%) 0 (0%) 0.003 no 27 (96.4%) 13 (100%) 2 (50.0%) 2 (100%)

The Global Burden of Cancer to Women Worldwide Parkin DM et al CA Cancer J Clin 2005;55;74-108